Christi Norton,  who represents Charles River Laboratories to its regional customers in the West, shared that the company recently acquired Argenta and Biofocus, adding significant early discovery expertise to existing in vivo pharmacology expertise.

The acquisition uniquely positions Charles River as a full-service CRO to support discovery and early development research in oncology, CNS, and other major therapeutic areas. A summary of Argenta’s and BioFocus’ acquisition can be found here.